Fundraising FoxAngenMed
1 known investors
Find your way into AngenMed
Sign up to find every way you can get introduced to AngenMed
- Your email: who you already know at AngenMed, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the AngenMed team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
Investors · 1
Frequently asked questions
- What does AngenMed do?
- AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
- Who are AngenMed's investors?
- AngenMed's investors include Maxpro Ventures.